Galenica AG: Half-year growth and upward revision of EBIT forecasts

Swiss company Galenica AG reports a significant 5% increase in sales in the first half of 2025, reaching CHF 1,995.4 million. Adjusted EBIT rose 10.9%, mainly driven by exceptional gains of CHF 5.4 million. Based on these results, Galenica is revising its EBIT forecast upwards to between 7% and 9% growth. The "Products & Care" and "Logistics & IT" segments contributed to this momentum.

Strong demand for prescription medications, particularly GLP-1-based weight-loss products and flu treatments, boosted sales growth. These positive developments were accompanied by a downward revision of penalties in two competition cases, which had a positive impact on the Logistics & IT sector.